home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Events -> Meetings and Conferences  

RNAi for Target Validation and as a Therapeutic

  June 15, 2006  

Keystone Symposia, Keystone, Colorado
January 28 - February 2, 2007

RNA Interference (RNAi) remains a promising new approach for gene silencing both in the context of post-genomic research on target validation and for potential therapeutic applications. As a tool for target validation, synthetic and DNA-based RNAi strategies have been applied in both academia and industry, with significant recent advances in understanding selection of siRNA sequences, optimization for potency and specificity, mechanisms for activation of innate immunity, and vector-based methods for whole-genome siRNA libraries. Several applications of these technologies will be presented. As a therapeutic strategy, synthetic and DNA-based RNAi strategies have advanced to pre-clinical animal models and early clinical testing. These approaches have explored multiple strategies to address the delivery hurdle, and include both local and systemic administration opportunities. The goals of the meeting are to discuss the latest advances in RNAi technology as both a research tool and therapeutic strategy.
Organized by: John M. Maraganore and Stephen H. Friend
Invited Speakers: - Victor Ambros, Dartmouth Medical School
- Neil Aronin, University of Massachusetts Medical School
- C. Bennett, ISIS Pharmaceuticals, Inc.
- Thijn Brummelkamp, Whitehead Institute for Biomedical Research
- Carlo Croce, Ohio State University College of Medicine
- Beverly Davidson, University of Iowa
- Stephen Fesik, Abbott Laboratories
- Witold Filipowicz, Friedrich Miescher Institute for Biomedical Research
- Jonathan Hall, Novartis Institutes for BioMedical Research
- Gregory Hannon, Cold Spring Harbor Laboratory
- Mark Kay, Stanford University
- Anna Krichevsky, Brigham and Women's Hospital, Harvard Medical School
- Judy Lieberman, Harvard Medical School
- Peter Linsley, Rosetta Inpharmatics LLC
- Vivek Mittal, Cold Spring Harbor Laboratory
- Ronald Plasterk, Hubrecht Laboratory
- John Rossi, Beckman Research Institute of the City of Hope
- Phillip Sharp, Massachusetts Institute of Technology
- Erik Sontheimer, Northwestern University
- Markus Stoffel, Rockefeller University
- Ralph Tripp, University of Georgia
- Thomas Tuschl, Rockefeller University
- Akshay Vaishnaw, Alnylam Pharmaceuticals Inc.
- Hans-Peter Vornlocher, Alnylam Europe AG
- Phillip Zamore, University of Massachusetts Medical School
- Tracy Zimmermann, Alnylam Pharmaceuticals Inc.
Deadline for Abstracts: Sept. 28, 2006
Registration: Please see website
E-mail: info@keystonesymposia.org
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.